GLYC - GlycoMimetics, Inc.
| Previous Close | 4.4800 |
| Open | 4.4800 |
| Bid | 4.3500 x 800 |
| Ask | 6.4800 x 1400 |
| Day's Range | 4.3300 - 4.6900 |
| 52 Week Range | 2.6400 - 14.8100 |
| Volume | 452,622 |
| Avg. Volume | 978,093 |
| Market Cap | 199.553M |
| Beta (3Y Monthly) | 2.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2840 |
| Earnings Date | Aug 3, 2017 - Aug 7, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.00 |
- Thomson Reuters StreetEvents
Edited Transcript of GLYC earnings conference call or presentation 1-Aug-19 12:30pm GMT
Q2 2019 GlycoMimetics Inc Earnings Call
- GuruFocus.com
Analysts Recommend These 2 Falling Knives
NuCana, GlycoMimetics present interesting opportunities Continue reading...
- Zacks
Are Options Traders Betting on a Big Move in GlycoMimetics (GLYC) Stock?
Investors need to pay close attention to GlycoMimetics (GLYC) stock based on the movements in the options market lately.
- Benzinga
A Look At Benzinga Pro's Most-Searched Tickers For August 5, 2019
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Allakos (NASDAQ: ALLK ) shares were up 112.6% ...
- MarketWatch
GlycoMimetics stock down 53% after Phase 3 trial failure
Shares of GlycoMimetics Inc. fell 53% in premarket trade Monday after the company announced Friday evening that a Phase 3 trial of a sickle-cell disease drug, developed in partnership with Pfizer Inc. , did not meet primary or secondary endpoints. Shares of Pfizer were down 0.8% in premarket trade on Monday. The drug, called rivipansel, is meant to treat vaso-occlusive crises (VOC), a common clinical manifestation of sickle-cell disease that occurs when sickled red blood cells irritate the lining of blood vessels and cause a painful inflammatory response that blocks those vessels. Such episodes can require hospitalization and are commonly treated with pain relievers like opioids and NSAIDs. Researchers were looking at whether rivipansel could shorten the time patients were hospitalized and decrease opioid consumption during treatment. "We are disappointed with the results, as we have been working in close partnership with the SCD community to advance rivipansel as a potential treatment option for acute VOC. We plan to share the study data at an upcoming scientific meeting as we want to ensure the learnings from this trial help inform future sickle cell programs that aim to improve care for SCD patients experiencing a VOC," said Brenda Cooperstone, Pfizer's chief development officer of rare disease. Shares of Pfizer have fallen 13% in the year to date through Friday, while GlycoMimetics stock has fallen 3.6%. The S&P 500 has gained 17%.
- TheStreet.com
GlycoMimetics Plummets After Phase 3 Trial of Sickle Cell Treatment Fails
The company announces that rivipansel, which was developed in partnership with Pfizer, didn't meet primary or secondary endpoints.
- Business Wire
GlycoMimetics Reports Top-line Results From Pfizer’s Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease
GlycoMimetics, Inc. (GLYC) reported that Pfizer Inc. (PFE) announced today that the Phase 3 Rivipansel (GMI-1070): Evaluating Safety, Efficacy and Time to Discharge (RESET) pivotal study did not meet its primary or key secondary efficacy endpoints. The objective of the trial was to evaluate the efficacy and safety of rivipansel in patients aged six and older with sickle cell disease (SCD) who were hospitalized for a vaso-occlusive crisis (VOC) and required treatment with intravenous (IV) opioids. “We are both surprised and deeply disappointed by this outcome, as we had strongly hoped that rivipansel would have a positive benefit for people living with sickle cell disease,” said Rachel King, Chief Executive Officer of GlycoMimetics.
Motley FoolGlycoMimetics (GLYC) Q2 2019 Earnings Call Transcript
GLYC earnings call for the period ending June 30, 2019.
- Zacks
GlycoMimetics Enters Oversold Territory
GlycoMimetics, Inc. (GLYC) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
- Business Wire
GlycoMimetics to Present at Jefferies 2019 Healthcare Conference
GlycoMimetics, Inc. today announced that Chief Executive Officer Rachel King will provide a corporate update at the Jefferies 2019 Healthcare Conference, on June 5 at 2:00 p.m.
- Thomson Reuters StreetEvents
Edited Transcript of GLYC earnings conference call or presentation 2-May-19 12:30pm GMT
Q1 2019 GlycoMimetics Inc Earnings Call
- Insider Monkey
Here’s What Hedge Funds Think About GlycoMimetics, Inc. (GLYC)
How do you pick the next stock to invest in? One way would be to spend hours of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
- Business Wire
GlycoMimetics, Inc. Announces Enrollment Completed for Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease
GlycoMimetics, Inc. (GLYC) today announced that patient enrollment has been completed in the Phase 3 RESET (Rivipansel: Evaluating Safety, Efficacy and Time to Discharge) clinical trial, which is evaluating the efficacy and safety of rivipansel for the acute treatment of vaso-occlusive crisis (VOC) in sickle cell disease (SCD). In 2011, GlycoMimetics and Pfizer Inc. (PFE) entered into a worldwide license agreement for the development and, if approved by applicable regulatory authorities, commercialization of rivipansel. Since completion of the Phase 2 clinical trial, Pfizer, has been responsible for clinical development of rivipansel, including the RESET clinical trial.
- Motley Fool
GlycoMimetics (GLYC) Q1 2019 Earnings Call Transcript
GLYC earnings call for the period ending March 31, 2019.
- Associated Press
GlycoMimetics: 1Q Earnings Snapshot
On a per-share basis, the Rockville, Maryland-based company said it had a loss of 33 cents. The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment ...
- Business Wire
GlycoMimetics Reports First Quarter 2019 Results and Recent Operational Highlights
ROCKVILLE, Md.-- -- Enrolled first patient in National Cancer Institute -sponsored Phase 3 trial of uproleselan in older adults with previously untreated acute myeloid leukemia Announced plans to initiate a trial of GMI-1359 in individuals with breast cancer in collaboration with the Duke Cancer Institute Established transition plan to new Chairman of Board of Directors GlycoMimetics, Inc. today reported ...
- ACCESSWIRE
GlycoMimetics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 2, 2019 / GlycoMimetics, Inc. (NASDAQ: GLYC ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 2, 2019 at 8:30 AM Eastern ...
- Business Wire
GlycoMimetics Bolsters Executive Team with Appointment of Dr. Eric Feldman as Vice President, Clinical Development, and Christian Dinneen-Long as Vice President, Corporate Counsel
GlycoMimetics, Inc. (GLYC) today announced the addition of two senior executives to its executive management team. Eric Feldman, M.D., a specialist in leukemia and bone marrow disorder therapies, has been appointed Vice President of Clinical Development. Christian Dinneen-Long, an attorney with deep experience in the biotechnology industry, has been appointed Vice President and Corporate Counsel.
- Business Wire
GlycoMimetics to Report First Quarter 2019 Financial Results on May 2, 2019
GlycoMimetics, Inc. announced today that it will host a conference call and webcast to report its first-quarter 2019 financial results on Thursday, May 2, 2019, at 8:30 a.m.
- Business Wire
GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML
GlycoMimetics, Inc. (GLYC) announced today dosing of the first patient in a Phase 3 clinical trial being conducted under the auspices of a Cooperative Research and Development Agreement (CRADA) between GlycoMimetics and the National Cancer Institute (NCI), part of the National Institutes of Health. The second in a series of trials designed to evaluate uproleselan across the continuum of care in AML, this NCI-sponsored study is evaluating the addition of uproleselan to a standard cytarabine/daunorubicin regimen (7&3) in older adults with previously untreated AML who are suitable for intensive chemotherapy.
- Business Wire
GlycoMimetics Announces Publication of Nature Cell Biology Paper Supporting Recently Announced Clinical Trial of GMI-1359
Data shows that E-selectin is key to tumor growth and metastasis to bone and provides further support for upcoming clinical trial in patients with metastatic breast cancer
- Thomson Reuters StreetEvents
Edited Transcript of GLYC earnings conference call or presentation 6-Mar-19 1:30pm GMT
Q4 2018 GlycoMimetics Inc Earnings Call
- Business Wire
GlycoMimetics Announces Plans to Initiate Breast Cancer Trial to Evaluate GMI-1359
GlycoMimetics, Inc. (GLYC) today announced plans to initiate a clinical trial of GMI-1359 in breast cancer patients whose tumors have spread to bone. GMI-1359 is a dual function antagonist that targets both E-selectin and CXCR4, both of which are involved in tumor trafficking and metastatic spread.
- Business Wire
GlycoMimetics to Present at Upcoming Investor Conferences
GlycoMimetics, Inc. today announced that senior management will present corporate updates at two upcoming investor conferences in April. Details are as follows:
